HRP20211116T1 - Derivati inozitola za upotrebu u patološkoj kristalizaciji - Google Patents
Derivati inozitola za upotrebu u patološkoj kristalizaciji Download PDFInfo
- Publication number
- HRP20211116T1 HRP20211116T1 HRP20211116TT HRP20211116T HRP20211116T1 HR P20211116 T1 HRP20211116 T1 HR P20211116T1 HR P20211116T T HRP20211116T T HR P20211116TT HR P20211116 T HRP20211116 T HR P20211116T HR P20211116 T1 HRP20211116 T1 HR P20211116T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- mol
- inositol derivatives
- pathological crystallization
- pathological
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 150000004001 inositols Chemical class 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
- C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
- C08G65/3358—Polymers modified by chemical after-treatment with organic compounds containing phosphorus having sulfur in addition to phosphorus
Claims (3)
1. Spoj opisan općom formulom (II)
[image]
gdje
- dva ili tri X su R1 i preostali X su OPO32-; i
- svaki R1 je polietilen glikol.
2. Spoj prema zahtjevu 1, pri čemu R1 je polietilen glikol i ima molekulsku masu između 100 g/mol i 3000 g/mol, posebno između 100 g/mol i 2500 g/mol, određenije približno 100 g/mol do. 2000 g/mol.
3. Spoj prema zahtjevu 1, opisan s bilo kojom od formula:
[image]
[image]
[image]
[image]
[image]
[image]
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199682 | 2015-12-11 | ||
| EP16164299 | 2016-04-07 | ||
| EP16173422 | 2016-06-07 | ||
| EP16819297.9A EP3386548B1 (en) | 2015-12-11 | 2016-12-12 | Inositol derivatives for use in pathological crystallization |
| PCT/EP2016/080657 WO2017098047A1 (en) | 2015-12-11 | 2016-12-12 | Inositol derivatives for use in pathological crystallization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211116T1 true HRP20211116T1 (hr) | 2021-10-15 |
Family
ID=57629577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211116TT HRP20211116T1 (hr) | 2015-12-11 | 2021-07-12 | Derivati inozitola za upotrebu u patološkoj kristalizaciji |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10624909B2 (hr) |
| EP (2) | EP3386548B1 (hr) |
| JP (2) | JP6958866B2 (hr) |
| KR (1) | KR102646016B1 (hr) |
| CN (2) | CN108367080B (hr) |
| AU (2) | AU2016368547B2 (hr) |
| BR (1) | BR112018011732A2 (hr) |
| CA (1) | CA3005933A1 (hr) |
| DK (1) | DK3386548T3 (hr) |
| EA (1) | EA037572B1 (hr) |
| ES (1) | ES2870521T3 (hr) |
| HR (1) | HRP20211116T1 (hr) |
| HU (1) | HUE055165T2 (hr) |
| IL (1) | IL259607B (hr) |
| LT (1) | LT3386548T (hr) |
| MX (1) | MX2018007130A (hr) |
| PL (1) | PL3386548T3 (hr) |
| SI (1) | SI3386548T1 (hr) |
| WO (1) | WO2017098047A1 (hr) |
| ZA (1) | ZA201803354B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108367080B (zh) * | 2015-12-11 | 2021-10-08 | 苏黎世联邦理工学院 | 用于病理性结晶的肌醇衍生物 |
| US20210347793A1 (en) * | 2018-09-18 | 2021-11-11 | Inositec Ag | Calcium oxalate crystallization inhibitors for renal disorders |
| WO2020074944A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
| MX2021008966A (es) | 2019-01-30 | 2021-11-04 | Sanifit Therapeutics S A | Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular. |
| EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
| RU2731816C1 (ru) * | 2020-03-16 | 2020-09-08 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Способ диагностики кальциноза коронарных артерий у пациента с вторичным гиперпаратиреозом, получающего заместительную почечную терапию гемодиализом |
| TW202206082A (zh) | 2020-04-30 | 2022-02-16 | 大陸商上海森輝醫藥有限公司 | 一種肌醇衍生物及其用途 |
| IL303032A (en) | 2020-11-20 | 2023-07-01 | Vifor Int Ag | HEXAKISPHOSPHATE inositol analogues for the treatment of kidney diseases associated with calcification |
| EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
| MX2023008749A (es) | 2021-01-26 | 2023-08-01 | Vifor Int Ag | Programa de dosificacion clinica de compuestos de fosfato de inositol-oligo(etilenglicol). |
| EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
| WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
| WO2024023359A1 (en) * | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
| WO2024047037A1 (en) | 2022-08-30 | 2024-03-07 | ETH Zürich | Compositions for parenteral sustained release delivery of hydrophilic drugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8605063D0 (sv) * | 1986-11-26 | 1986-11-26 | Matti Siren | Derivatives of cyclohexane |
| CA2650035C (en) * | 2006-04-27 | 2015-02-03 | Intezyne Technologies, Inc. | Poly (ethylene glycol) containing chemically disparate endgroups |
| ES2288126B2 (es) * | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| US8052931B2 (en) * | 2010-01-04 | 2011-11-08 | International Business Machines Corporation | Ultra low-power CMOS based bio-sensor circuit |
| WO2013045107A1 (en) * | 2011-09-29 | 2013-04-04 | Eth Zurich | Pharmaceutical compounds for use in the therapy of clostridium difficile infection |
| US9364490B2 (en) * | 2013-03-15 | 2016-06-14 | Laboratoris Sanifit, S.L. | Use of derivatives containing C—O—P bonds in patients with kidney failure |
| CN108367080B (zh) * | 2015-12-11 | 2021-10-08 | 苏黎世联邦理工学院 | 用于病理性结晶的肌醇衍生物 |
-
2016
- 2016-12-12 CN CN201680071651.7A patent/CN108367080B/zh active Active
- 2016-12-12 DK DK16819297.9T patent/DK3386548T3/da active
- 2016-12-12 KR KR1020187015987A patent/KR102646016B1/ko active IP Right Grant
- 2016-12-12 BR BR112018011732A patent/BR112018011732A2/pt not_active Application Discontinuation
- 2016-12-12 EP EP16819297.9A patent/EP3386548B1/en active Active
- 2016-12-12 US US16/060,980 patent/US10624909B2/en active Active
- 2016-12-12 SI SI201631268T patent/SI3386548T1/sl unknown
- 2016-12-12 MX MX2018007130A patent/MX2018007130A/es unknown
- 2016-12-12 ES ES16819297T patent/ES2870521T3/es active Active
- 2016-12-12 HU HUE16819297A patent/HUE055165T2/hu unknown
- 2016-12-12 LT LTEP16819297.9T patent/LT3386548T/lt unknown
- 2016-12-12 EA EA201891364A patent/EA037572B1/ru unknown
- 2016-12-12 CA CA3005933A patent/CA3005933A1/en active Pending
- 2016-12-12 WO PCT/EP2016/080657 patent/WO2017098047A1/en active Application Filing
- 2016-12-12 CN CN202111074549.1A patent/CN113788855B/zh active Active
- 2016-12-12 AU AU2016368547A patent/AU2016368547B2/en active Active
- 2016-12-12 EP EP21158307.5A patent/EP3848053A1/en active Pending
- 2016-12-12 PL PL16819297T patent/PL3386548T3/pl unknown
- 2016-12-12 JP JP2018528966A patent/JP6958866B2/ja active Active
-
2018
- 2018-05-21 ZA ZA2018/03354A patent/ZA201803354B/en unknown
- 2018-05-25 IL IL259607A patent/IL259607B/en unknown
-
2021
- 2021-07-12 HR HRP20211116TT patent/HRP20211116T1/hr unknown
- 2021-09-29 JP JP2021159270A patent/JP7300685B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200542A patent/AU2022200542B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211116T1 (hr) | Derivati inozitola za upotrebu u patološkoj kristalizaciji | |
| HRP20192202T1 (hr) | Acc inhibitori i njihove upotrebe | |
| HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
| CR20140464A (es) | Compuestos de heterociclilo | |
| SMT201600142B (it) | Indoli come agenti antivirali contro il virus respiratorio sinciziale | |
| RS53301B (en) | TIOACETATE COMPOUNDS, COMPOSITIONS AND USE PROCEDURES | |
| CU20170160A7 (es) | Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
| CO6741214A2 (es) | Composiciones pesticidas y procesos relacionados | |
| BR112014011938A2 (pt) | combinação de formulação de dois compostos antivirais | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY34763A (es) | Inhibidores de la agregación plaquetaria | |
| FR2993354B1 (fr) | Refroidisseur d'air de suralimentation | |
| FR2988609B1 (fr) | Formulation pour l'hormonotherapie | |
| DK2985284T3 (da) | Dicarboxylsyre bisamid derivater, brug heraf, farmaceutiske sammensætninger baseret derpå og metoder til fremstilling af dicarboxylsyre bisamid derivater | |
| GT201500235A (es) | Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3) | |
| BR112013016223A2 (pt) | películas e composições compreendendo as mesmas | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| PH12016500461A1 (en) | Polyethylene glycol-containing composition | |
| UY34469A (es) | Composicion herbicida | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| BR112015004348A2 (pt) | célula de fluxo de permeabilidade e sistema de condutância hidráulica | |
| BR112015004494A2 (pt) | célula de fluxo de permeabilidade e sistema de condutância hidráulica | |
| GT201200066A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| EA201400882A1 (ru) | Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях | |
| IT1400702B1 (it) | Apparecchiatura per l'imballaggio di carichi con pellicola termoretraibile, dotata di bruciatori regolabili. |